Spots Global Cancer Trial Database for Stereotactic Radiotherapy and Image-guided Intensity Modulated Radiotherapy for Spinal Metastatic Tumors
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Stereotactic Radiotherapy and Image-guided Intensity Modulated Radiotherapy for Spinal Metastatic Tumors
Official Title: Stereotactic Radiotherapy and Conventionally-fractionated-image-guided Intensity Modulated Radiotherapy for Spinal Metastatic Tumors：A Prospective Multicenter Cohort Study
Study ID: NCT03963713
Study Description
Brief Summary: Data of 100 patients with spinal metastatic tumor who received stereotactic radiotherapy or conventionally-fractionated image-guided intensity-modulated radiotherapy in the multi-center of the research group from July 2019 to June 2021 will be collected, as well as their follow-up data.Previous treatment and follow-up data will be analyzed to evaluate the clinical efficacy comparison of stereotactic radiotherapy and conventionally-fractionated image-guided intensity-modulated radiotherapy for spinal metastatic tumors, local control rate and side effects, and to clarify the effectiveness and safety of different doses of radiotherapy.
Detailed Description: In this study, Data of 100 patients with spinal metastatic tumor who received stereotactic radiotherapy or conventionally-fractionated image-guided intensity-modulated radiotherapy in the multi-center of the research group from July 2019 to June 2021 will be collected, as well as their follow-up data.The metastases were treated with SBRT.Using multimodal image fusion to outline the target area.PTV = GTV + 0-10mm Target volume radiation dose: The range of BED value of radiotherapy was 60-72 when the distance between the tumor and gastrointestinal tract or spinal cord was more than 5 mm (alpha/beta=10) and 51.3-59.5 when the distance between the tumor and gastrointestinal tract or spinal cord was less than 5 mm (alpha/beta=10).The metastases were treated with Conventionally-fractionated image- guided Intensity modulated radiotherapy.Using multimodal image fusion to outline the target area.The dose of the target volume radiotherapy dose is 30 Gy/10f or 40Gy/20f.Previous treatment and follow-up data will be analyzed to evaluate the clinical efficacy comparison of stereotactic radiotherapy and conventionally-fractionated image-guided intensity-modulated radiotherapy for spinal metastatic tumors, local control rate and side effects, and to clarify the effectiveness and safety of different doses of radiotherapy.
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Peking University Third Hospital, Beijing, Beijing, China
The fifth medical center of PLA general hospital, BeiJing, Beijing, China
Guangxi ruikang hospital, NanNing, Guangxi, China
Third Affiliated Hospital of Guizhou Medical University, GuiYang, Guizhou, China
GEM flower hospital of Liaohe oil field Tang-Du Hospital, Panjin, Liaoning, China
Hiser Medical Center of Qingdao, Qingdao, Shandong, China
Qingdao chengyang people's hospital, Qingdao, Shandong, China
Second hospital of Shanxi Medical University, TaiYuan, Shanxi, China
Tangdu hospital, Xian, Shanxi, China
Mianyang Central Hospital, Mianyang, Sichuan, China
Contact Details
Name: Junjie Wang, MD
Affiliation: Peking University Third Hospital
Role: STUDY_CHAIR
Name: Fei Xu, M Med
Affiliation: Peking University Third Hospital
Role: STUDY_DIRECTOR
Name: Hongqing Zhuang, M Med
Affiliation: Peking University Third Hospital
Role: PRINCIPAL_INVESTIGATOR
Name: Xiaobo Du, MD
Affiliation: Mianyang Central Hospital
Role: PRINCIPAL_INVESTIGATOR
Name: Jie Li, M Med
Affiliation: Mianyang Central Hospital
Role: PRINCIPAL_INVESTIGATOR
Name: Xiang Song, M Med
Affiliation: Second Hospital of Shanxi Medical University
Role: PRINCIPAL_INVESTIGATOR
Name: Lei Zhang, M Med
Affiliation: Second Hospital of Shanxi Medical University
Role: PRINCIPAL_INVESTIGATOR
Name: Jianguo Zhang, M Med
Affiliation: Qingdao chengyang people's hospital
Role: PRINCIPAL_INVESTIGATOR
Name: Peng Liu, M Med
Affiliation: Qingdao Hiser Medical Group
Role: PRINCIPAL_INVESTIGATOR
Name: Xuezhang Duan, MD
Affiliation: Beijing 302 Hospital
Role: PRINCIPAL_INVESTIGATOR
Name: Zuping Lian, MD
Affiliation: Guangxi Ruikang Hospital
Role: PRINCIPAL_INVESTIGATOR
Name: Liang Liu, MD
Affiliation: Third Affiliated Hospital of Guizhou Medical University
Role: PRINCIPAL_INVESTIGATOR
Name: Longhai Shen, M Med
Affiliation: Panjin Liaohe Oilfield Gem Flower Hospital
Role: PRINCIPAL_INVESTIGATOR
Name: Dongjie He, M Med
Affiliation: Tang-Du Hospital
Role: PRINCIPAL_INVESTIGATOR
Name: Xuemin Li, MD
Affiliation: Peking University Third Hospital
Role: PRINCIPAL_INVESTIGATOR
Name: Yi Chen, MD
Affiliation: Peking University Third Hospital
Role: PRINCIPAL_INVESTIGATOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
